Abstract: The present disclosure relates to compounds of formula (I). Compounds of formula (II), Compounds of formula (III), Compounds of formula (IV), Compounds of formula (V), Compounds of formula (VI), Compounds of formula (VII), in particular inhibitors if AhR, pharmaceutical formulation comprising any one of the same, use of said compounds or compositions in treatment, in particular treatment of cancer.

Abstract: The invention provides compounds of formula (I), their pharmaceutically acceptable salts and prodrugs thereof for use in preventing, inhibiting or treating a disease caused by a mutation in the gene coding for hydroxymethylbilane synthase, in particular for preventing, inhibiting or treating acute intermittent porphyria: (I) wherein: A is selected from N and CR10 (wherein R10 is H, —NO2, C1-6 haloalkyl or —C(O)R17 in which R17 is H or C1-6 alkyl); Z is selected from N and CR9 (wherein R9 is H, halogen (e.g. F, Cl, Br or I) or —OR16 in which R16 is H, C1-6 haloalkyl, or optionally substituted C1-6 alkyl); L is selected from —CH2—, —C(O)—, —CH(OH)—, —C(O)—NR?—, and —NR?—C(O)— (wherein R? is H or C1-3 alkyl, e.g. —CH3); R1 is H; R2 is selected from H, halogen (e.g.

Abstract: The present invention relates to compounds of formula I wherein A1, A2, A3, R1, R2, R3, R4, R5, R6, L, Ar and Q are each as defined herein. The compounds of the present invention are inhibitors of autotaxin (ATX) enzyme activity. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions (e.g. fibrosis) in which ATX activity is implicated.

Abstract: The present invention relates compounds of the general formula (I) or (III) which are ARH inhibitors, methods for preparing said compounds, pharmaceutical compositions and combinations comprising said compounds and the use of said compounds and pharmaceutical compositions for the treatment or prevention of diseases, in particular cancer or conditions with dysregulated immune functions, or other conditions associated with aberrant AHR signalling, as a sole agent of in combination with other active ingredients. Such compounds may also be of utility in the expansion of hematopoietic stem cells (HSCs) and the use of HSCs in autologous or allogenic transplantation for the treatment of patients with inherited immunological and autoimmune diseases and diverse hematopoietic disorders.

Abstract: The present disclosure relates to compounds of formula (I), which are suitable as AhR modulators, in particular AhR inhibitors. The disclosure also relates to compositions comprising said compounds and use of said compounds or compositions in treatment, in particular in the treatment of cancer. The disclosure further relates to methods of preparing said compounds.

Abstract: The present invention relates to compounds of formula I wherein A1, A2, A3, R1, R2, R3, R4, R5, R6, L, Ar and Q are each as defined herein. The compounds of the present invention are inhibitors of autotaxin (ATX) enzyme activity. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions (e.g. fibrosis) in which ATX activity is implicated.

Abstract: The present invention relates to compounds of formula I, wherein A1, A2, A3, R1, R2, R3, R4, R5, R6, L, Ar and Q are each as defined herein. The compounds of the present invention are inhibitors of autotaxin (ATX) enzyme activity. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions (e.g. fibrosis) in which ATX activity is implicated.

Abstract: The present invention relates to compounds of formula I, wherein A1, A2, A3, R1, R2, R3, R4, R5, R6, L, Ar and Q are each as defined herein. The compounds of the present invention are inhibitors of autotaxin (ATX) enzyme activity. The present invention also relates to processes for the preparation of these compounds, to pharmaceutical compositions comprising them, and to their use in the treatment of proliferative disorders, such as cancer, as well as other diseases or conditions (e.g. fibrosis) in which ATX activity is implicated.

Abstract: A clip is disclosed which can be used to fabricate the lattice structure of reinforcing rods of the type used in the construction of steel rod reinforced concrete slabs. An apparatus to fasten those clips in position is also disclosed The preferred clip (1) has a substantially rectangular body (2). A recess (3) extends from a first face (4) of the body (2) towards an opposite face (5). The recess (3) terminates in an arcuate portion (6). The inner edges (7a, b) of the recess (3) are convergent towards the arcuate portion (6). The apparatus has an aperture (13) in a base plate (12). Stops (18a, b, c) on the plate (12) suitably position the apparatus whereupon a shearing plate (32) can shear a clip (1) from a stack of such clips to pass through the aperture (13) wherein the arcuate portion (6) of the clip (1) engages the upper rod (16). A pair of pivoting J-shaped arms (21a, b) are then actuated which bend the lower portions of the clip (1) around the lower rod (17) securing the two rods (16, 17) together.

Abstract: Heat storage and transfer system and method in which a liquid-solid phase change material and a liquid-vapor phase change material selected for coaction with each other are disposed in a container with a body of the liquid phase of the liquid-vapor material in continuous contact with a body of the liquid phase of the liquid-solid material for superior heat transfer between the materials for giving up and transferring sensible heat and liquid to solid phase change latent heat to vaporize liquid-vapor phase change material and vapor to liquid phase change latent heat to a condenser/heat exchanger and also for superior heat transfer from a heat source such as a solar or electric heater by giving up the heat of condensation of a vapor phase to a solid-liquid material which accepts the heat as sensible heat and as heat of melting.

Abstract: A container holds a heat storage medium such as aqueous sodium thiosulfate having properties of melting into a liquid and crystallizing into a solid and saturated solution in a particular temperature range and of storing energy when converted to the molten state and of releasing such stored energy when crystallized. The sodium thiosulfate liquid may be chemically basic by the addition to the liquid of a suitable soluble additive material such as disodium hydrogen phosphate or trisodium phosphate or both. First and second tubes made from a suitable heat conducting material such as aluminum are disposed in the container in spaced and nested relationship to one another. The tubes may be joined by connecting members also made from aluminum. The first tubes are connected to provide for the circulation of a first fluid through the tubes to transfer energy to the heat storge medium for melting the material and further heating it above the melting interval.